Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1961 1
1962 1
1964 1
1966 1
1967 1
1976 2
1978 5
1979 6
1980 3
1981 2
1982 4
1983 1
1984 1
1986 2
1987 2
1989 1
1990 3
1991 2
1994 6
1995 1
1996 2
1997 2
1998 4
1999 11
2000 14
2001 26
2002 16
2003 20
2004 20
2005 23
2006 29
2007 22
2008 22
2009 18
2010 12
2011 20
2012 21
2013 19
2014 17
2015 31
2016 20
2017 23
2018 21
2019 17
2020 30
2021 23
Text availability
Article attribute
Article type
Publication date

Search Results

483 results
Results by year
Filters applied: . Clear all
Page 1
TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.
Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi SS. Udagawa H, et al. Among authors: ohashi a. Mol Cancer Res. 2019 Nov;17(11):2233-2243. doi: 10.1158/1541-7786.MCR-19-0419. Epub 2019 Aug 29. Mol Cancer Res. 2019. PMID: 31467113 Free PMC article.
Discovery of a Novel, Highly Potent, and Selective Thieno[3,2-d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent.
Kurasawa O, Miyazaki T, Homma M, Oguro Y, Imada T, Uchiyama N, Iwai K, Yamamoto Y, Ohori M, Hara H, Sugimoto H, Iwata K, Skene R, Hoffman I, Ohashi A, Nomura T, Cho N. Kurasawa O, et al. Among authors: ohashi a. J Med Chem. 2020 Feb 13;63(3):1084-1104. doi: 10.1021/acs.jmedchem.9b01427. Epub 2020 Jan 14. J Med Chem. 2020. PMID: 31895562
483 results